Document:

Loan Agreement

 Exhibit 10.3
 LOAN AGREEMENT 
   
 among 
 
   BOSTON SCIENTIFIC
CORPORATION
  
as Purchaser,
  
 and 
  
 CORAUTUS GENETICS INC.
  
 and 
  
 VASCULAR GENETICS INC. 
  
 as Issuers 
  
 Dated as of July 30, 2003

  TABLE OF CONTENTS

	 	 	 
			 Page
 
	 	ARTICLE I	 
	  	DEFINITIONS AND ACCOUNTING TERMS	 
	 	 	 
	SECTION 1.01	Certain Defined Terms	1 
	SECTION 1.02	Additional Definitions	3 
	SECTION 1.03	Interpretation and Rules of Construction	3 
	SECTION 1.04	Accounting Terms	4 
	 	ARTICLE II	 
	 	SUBSCRIPTION FOR THE NOTES	 
	 	 	 
	SECTION 2.01	Issuance of Notes	4 
	SECTION 2.02	Request for Funding	4 
	 	ARTICLE III	 
	 	CONDITIONS TO SUBSCRIPTIONS	 
	 	 	 
	SECTION 3.01	Conditions Precedent to Subscription for Each Note	5 
	 	ARTICLE IV	 
	  	TERMINATION	 
	 	 	 
	SECTION 4.01	Termination	6 
	 	ARTICLE V	 
	 	MISCELLANEOUS	 
	 	 	 
	SECTION 5.01	Public Announcements and Publications	6 
	SECTION 5.02	Amendments, Etc	6 
	SECTION 5.03	Notices	7 
	SECTION 5.04	No Waiver; Remedies	8 
	SECTION 5.05	Treatment of Note	8 
	SECTION 5.06	Costs and Expenses	8 
	SECTION 5.07	Binding Effect	8 
	SECTION 5.08	Survival	8 
	SECTION 5.09	Severability	8 
	SECTION 5.10	Entire Agreement	8 
	SECTION 5.11	No Third Party Beneficiaries	8 
	SECTION 5.12	Governing Law; Jurisdiction and Enforcement	8 
	SECTION 5.13	Dispute Resolution	9 
	SECTION 5.14	Counterparts	9 
	SECTION 5.15	Waiver of Jury Trial	9 

 i

  Exhibit A -       Form of Senior Convertible Promissory Note
 Exhibit B -       
Form of Notice of Borrowing
 Exhibit C -        Form of Opinion of Counsel to the Company
 ii

  Exhibit 10.3
 LOAN AGREEMENT
                      LOAN AGREEMENT (this “Agreement”) is made and entered into this 30th day
of July, 2003, among CORAUTUS GENETICS INC., a Delaware corporation (“Parent”), and its wholly-owned subsidiary, VASCULAR GENETICS INC., a Delaware corporation (“VGI” and, together with the Parent, the
“Issuers”), and BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (the “Purchaser” and, together with the Issuers, the “Parties”).
                      WHEREAS, pursuant to the Investment Agreement, dated July 30, 2003, between Parent and Purchaser
(the “Investment Agreement”), Parent and Purchaser agreed, subject to the conditions set forth in the Investment Agreement, to enter into this Agreement, an Investor Rights Agreement, a Development Agreement (the
“Development Agreement”), a Distribution Agreement and a Patent Sublicense Agreement (collectively, with this Agreement and the Investment Agreement, the “Transaction Documents”); and
                      WHEREAS, the Purchaser is willing to fund the Issuers’ research and development and clinical
trials conducted in accordance with the Development Agreement, by subscribing for, subject to the terms and conditions of this Agreement, up to three senior convertible promissory notes of the Issuers, each in principal amount of U.S.
$5,000,000;
                      NOW, THEREFORE, in consideration of the premises and the mutual
representations and warranties, agreements and covenants hereinafter set forth, the Parties hereby agree as follows:
 ARTICLE I
 DEFINITIONS AND ACCOUNTING TERMS
                      SECTION
1.01  Certain Defined Terms.  As used in this Agreement, the following terms shall have the following meanings (such meanings to be equally applicable to both the singular and plural forms of the terms defined):

		
	  	           ”Action” means any claim, action, suit, arbitration, inquiry, proceeding or investigation by or before any Governmental
Authority.

 

		
	  	           ”Change of Control” means (in one transaction or a series of transactions) (i) any Person or “group” of Persons (determined
based on Rule 13d-5(b) under the Exchange Act), other than one of the Issuers, becomes the “beneficial owner” (as defined under Rule 13d-3 under the Exchange Act) of more than 50% of the equity securities of either Issuer, (ii) individuals
who on the date of this Agreement constituted the board of directors of Parent (together with any new directors whose election by Parent’s board of directors or whose nomination by Parent’s board of directors for election by Parent’s
stockholders was approved by a vote of at least a majority of the members of Parent’s board of directors then in office who either were members of Parent’s board of directors on the date of this Agreement or whose election or nomination
for election was previously so approved) cease for any reason to constitute a majority of the members of Parent’s board of directors then in office, (iii) Parent conveys, transfers or leases all or 

 

		
	  	 substantially all of its assets to any Person, (iv) after giving effect to any merger, consolidation or reorganization of Parent, the stockholders of Parent immediately prior to such merger, consolidation or
reorganization do not hold more than 50% of the equity securities of the surviving corporation, or any other Person or “group” (as defined above) holds 30% or more of the equity securities of the surviving corporation, or (v) the board of
directors of Parent approves any of the foregoing or Parent enters into a definitive agreement with any Person with respect to any of the foregoing.

 

		
	  	           ”Distribution Agreement” means the Distribution Agreement entered into as of the date hereof between the Parent and the
Purchaser.

 

		
	  	           ”Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

		
	  	           ”Governmental Authority” means any United States or non-United States federal, national, supranational, state, provincial, local, or
similar government, governmental, regulatory or administrative authority, agency or commission or any court, tribunal, or judicial or arbitral body.

 

		
	  	           ”Governmental Order” means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any
Governmental Authority.

 

		
	  	           ”Investor Rights Agreement” means the Investor Rights Agreement entered into as of the date hereof between the Parent and the
Purchaser.

 

		
	  	           ”Law” means any applicable United States or non-United States federal, national, supranational, state, provincial, local or similar
statute, law, ordinance, regulation, rule, code, order, requirement or rule of law.

 

		
	  	           ”Milestones” means the following:

 

		
	 	          ”Milestone I” means the initiation of a Phase IIb clinical trial for the Product not later than June 30, 2004;

		
	  	          ”Milestone II” means the closing of an equity round of financing, after the date hereof with net proceeds received by the Company of at
least $10,000,000, and future commitments of at least an additional $10,000,000; and

 

		
		          ”Milestone III” means the enrollment of at least 100 patients in a phase III clinical trial for the Product.

		
	  	           Milestones may be met in any order.

 

		
	  	           ”Net Current Assets” means, with respect to any Person, (a) all assets of such Person that would be classified as current assets, after
deducting appropriate and adequate reserves therefrom in each case in which a reserve is proper in accordance with GAAP, less (b) all liabilities of such Person that would be classified as current liabilities, in the case of (a) and (b) in
accordance with GAAP, on the balance sheet of a company conducting a business the same as or similar to that of such Person.

 
 2

		
	  	           ”Patent Sublicense Agreement” means the Patent Sublicense Agreement entered into as of the date hereof between the Parent and the
Purchaser.

 

		
	  	           ”Person” means any individual, partnership, firm, corporation, limited liability company, association, trust, unincorporated organization
or other entity, as well as any syndicate or group that would be deemed to be a person under Section 13(d)(3) of the Exchange Act.

 

		
	  	           ”Product” has the meaning assigned to such term in the Development Agreement.

 

		
	  	           ”Solvent” and “Solvency” mean, with respect to any Person on any date of determination, that on such date (a) the fair
value of the property of such Person is greater than the total amount of liabilities, including, without limitation, contingent liabilities, of such Person, (b) the present fair salable value of the assets of such Person is not less than the amount
that will be required to pay the probable liability of such Person on its debts as they become absolute and matured, (c) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person’s ability
to pay such debts and liabilities as they mature and (d) such Person is not engaged in business or a transaction, and is not about to engage in business or a transaction, for which such Person’s property would constitute an unreasonably small
capital. The amount of contingent liabilities at any time shall be computed as the amount that, in the light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or
matured liability.

 
                      SECTION 1.02  Additional
Definitions.  The following terms have the meanings assigned to such terms in the corresponding Sections set forth below:

	 				
	 	Definition 
 		Location 
 	
	 	“Agreement”	 	Preamble	 
	 	“Development Agreement”	 	Recitals	 
	 	“GAAP”	 	1.04	 
	 	“Investment Agreement”	 	Recitals	 
	 	“Issuers”	 	Preamble	 
	 	“Note”	 	2.01	 
	 	“Notice of Borrowing”	 	2.02	 
	 	“Notice of Disagreement”	 	5.13	 
	 	“Parties”	 	Preamble	 
	 	“Parent”	 	Preamble	 
	 	“Purchaser”	 	Preamble	 
	 	“Transaction Documents”	 	Recitals	 
	 	“VGI”	 	Preamble	 

                      SECTION
1.03   Interpretation and Rules of Construction.  In this Agreement, except to the extent that the context otherwise requires:
 3

		
	  	  (i)       when a reference is made in this Agreement to an Article, Section, Exhibit or Schedule, such reference is to an Article or Section of, or a Schedule to, this Agreement
unless otherwise indicated;

 

		
	  	  (ii)       headings for this Agreement are for reference purposes only and do not affect in any way the meaning or interpretation of this Agreement;

		
	  	  (iii)       whenever the words “include”, “includes” or “including” are used in this Agreement, they are deemed to be followed by the words
“without limitation”;

 

		
	  	  (iv)       the words “hereof”, “herein” and “hereunder” and words of similar import, when used in this Agreement, refer to this Agreement as a whole
and not to any particular provision of this Agreement;

 

		
	  	  (v)       all terms defined in this Agreement have such defined meanings when used in any certificate or other document made or delivered pursuant hereto, unless otherwise defined
therein;

 

		
	  	  (vi)       the definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms;

 

		
	  	  (vii)       any Law defined or referred to herein or in any agreement or instrument that is referred to herein means such Law or statute as from time to time amended, modified or
supplemented, including by succession of comparable successor Laws; and

 

		
	  	  (viii)      all references in this Agreement to currency, monetary values and dollars shall mean United States (U.S.) dollars and all payments hereunder shall be made in United
States dollars.

 
                      SECTION 1.04   Accounting
Terms.  All accounting terms not specifically defined herein shall be construed in accordance with United States generally accepted accounting principles (“GAAP”).
 ARTICLE II
 SUBSCRIPTION FOR THE NOTES
                      SECTION 2.01   Issuance of Notes.  Upon the terms and subject to the
conditions contained in this Agreement, the Purchaser agrees to subscribe for up to three senior convertible promissory notes of the Issuers, each in principal amount of U.S. $5,000,000 and in the form attached as Exhibit A hereto (each a
“Note”).
                      SECTION 2.02  Request for
Funding.  The Issuers shall make any request of the Purchaser to subscribe for a Note by delivering a notice to the Purchaser, given not later than 3:00 P.M. (New York City time) ten (10) Business Days prior to the date of the proposed
issuance of the Note by the Issuers. Each such notice (a “Notice of Borrowing”) shall be made in writing, in substantially the form of Exhibit B hereto, specifying therein the requested date of
 4

  such issuance. Each Notice of Borrowing shall be irrevocable and binding on the Issuers. Subject to the terms and conditions of this Agreement, the Purchaser shall, before 3:00 P.M.
(New York City time) on the date of issuance, make such funds available to the Issuers as directed in the Notice of Borrowing.
 ARTICLE III
 CONDITIONS TO SUBSCRIPTIONS
                      SECTION 3.01  
Conditions Precedent to Subscription for Each Note.  The obligation of the Purchaser to subscribe for any Note shall be subject to the satisfaction (or waiver by the Purchaser in its sole discretion) of the conditions set forth in
this Article III, and each of the giving by the Issuers of the applicable Notice of Borrowing and the acceptance by Issuers of the proceeds of such Note subscription shall constitute a joint and several representation and warranty by the Issuers
that on the date of the issuance of such Note each of the following statements are true and correct in all respects):

		
	  	  (a)       the representations and warranties contained in Article III of such Note are true and correct in all material respects on and as of the date of the issuance of such
Note; provided that to avoid a second materiality qualification any representation and warranty that is qualified by materiality or Material Adverse Effect shall be true and correct in all respects as of the date of the issuance of such Note,
before and after giving effect to the issuance of such Note and to the application of the proceeds therefrom, as though made on and as of such date;

 

		
	  	  (b)       no event has occurred and is continuing that would constitute a Default (as defined in the Note);

 

		
	  	  (c)       there has not been any material breach by the Parent of any of the Transaction Documents, including, without limitation, a material breach by the Parent of its
representations and warranties set forth in the Investment Agreement or of its exclusivity obligations under the Distribution Agreement, in each case, which breach has not been remedied;

 

		
	  	  (d)       from and after the date of this Agreement, the Issuers shall have performed and observed in all material respects with every term, covenant and agreement contained in
Article IV of the form of Note attached as Exhibit A hereto; provided that to avoid a second materiality qualification any term, covenant and agreement contained in Article IV of the form of the Note that is qualified by materiality shall be
performed without any materiality qualifier, as if such covenants and agreements were fully set forth in this Agreement;

 

		
	  	  (e)       after giving effect to the issuance of the Note, the Net Current Assets of the Parent, on a consolidated basis, shall be in excess of $4,000,000 and the Issuer shall
provide the Purchaser evidence reasonably satisfactory of the compliance thereof;

 
 5

		
	 	            (f)         both immediately prior to issuing the Note and immediately after giving effect to the issuance of
the Note and the application of the proceeds therefrom, each Issuer, individually and together with its Subsidiaries collectively, shall be Solvent.

 

		
	 	            (g)         the Purchaser shall have received on or before the issuance of such Note, in form and substance
reasonably satisfactory to the Purchaser, certified copies of the resolutions of the Issuers approving the issuance of such Note, and all documents evidencing other necessary corporate action, if any, with respect thereto;

		
	 	            (h)         with respect to the issuance of each Note, the Purchaser shall have received an opinion of
counsel to the Company addressed to the Purchaser, substantially in the form attached hereto as Exhibit C;

 

		
	 	            (i)         Milestone I, Milestone II or Milestone III shall have been satisfied (it being understood that
Milestones may be met in any order but that a given Milestone, once applied to satisfy this condition precedent to subscription of a Note, may not be used to satisfy this condition precedent with respect to any subsequent Note issuance);
and

 

		
	 	            (j)         there shall be no Governmental Order in effect, and no Action shall be pending or threatened, in
each case against the Purchaser or an Issuer, that would be reasonably expected to materially adversely impair the benefits of any of the Transaction Documents to the Purchaser.

 
 ARTICLE IV
 TERMINATION
                    SECTION 4.01   Termination.    This Agreement shall terminate automatically upon any
of (a) the termination of any of the other Transaction Documents or (b) a Change of Control. Upon termination of this Agreement, the Purchaser shall have no further obligation to subscribe for any Notes hereunder.
 ARTICLE V
 MISCELLANEOUS
                    SECTION 5.01   Public Announcements and Publications.   Except as required by Law or
by the requirements of any securities exchange on which the securities of a Party hereto are listed, no Party shall make, or cause to be made, any press release or public announcement in respect of this Agreement or the transactions contemplated
hereby or otherwise communicate with any news media in respect of this Agreement or the transactions contemplated hereby without the prior written consent of the other Party, and the Parties shall cooperate as to the timing and contents of any such
press release or public announcement.
                    SECTION 5.02   Amendments,
Etc.   No amendment or waiver of any provision of this Agreement, nor consent to any departure by the Issuers or the Purchaser therefrom, shall in
 6

  any event be effective unless the same shall be in writing and signed by the other Party, and then such waiver or consent shall be effective only in the specific instance and for the
specific purpose for which given.
                    SECTION 5.03   Notices.    All
notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in person, by an internationally recognized overnight
courier service, by telecopy or registered or certified mail (postage prepaid, return receipt requested) to the respective Parties at the following addresses (or at such other address for a Party as shall be specified in a notice given in accordance
with this Section 5.03):

			
	 	(a) 	 if to either Issuer:

 

		
	  	Corautus Genetics Inc.
 430 Tenth Street, NW
 Suite S-204 
 Atlanta, GA 30318
 Telecopy: (404) 526-6218 
 Attention: Chief Executive Officer

 

		
	 	with a copy (which shall not constitute notice) to:

 

		
	 	McKenna Long & Aldridge LLP 
 303 Peachtree Street, Suite 5300 
 Atlanta, GA 30308 
 Telecopy: (404) 527-4198 
 Attention: Robert E. Tritt

 

			
	 	(b) 	 if to the Purchaser:

 

		
	 	Boston Scientific Corporation 
 One Boston Scientific Place
 Natick, MA 01760-1537
 Telecopy: (508) 650-8956 
 Attention: General Counsel

 

		
	 	with a copy (which shall not constitute notice) to:

 

		
	 	Shearman & Sterling LLP 
 599 Lexington Ave. 
 New York, New York 10022-6069
 Telecopy: (212) 848-7179 
 Attention: Clare O’Brien, Esq.

 
                    Any notice, if mailed and properly addressed with postage prepaid or if properly addressed and sent by pre-paid
courier service, shall be deemed given when received; any notice, if transmitted by facsimile, shall be deemed given when the confirmation of transmission thereof is received by the transmitter.
 7

                     SECTION 5.04   No Waiver; Remedies.   No
failure on the part of the Purchaser to exercise, and no delay in exercising, any right hereunder or under this Agreement shall operate as a waiver thereof; nor shall any single or partial exercise of any such right preclude any other or further
exercise thereof or the exercise of any other right.
                    SECTION 5.05   Treatment
of Note.   To the extent permitted by generally accepted accounting principles, the Issuers will treat, account and report this Note as debt and not equity for accounting purposes and with respect to any returns filed with federal,
state or local tax authorities.
                    SECTION 5.06   Costs and Expenses. Except
as otherwise specified in this Agreement or a Note, all costs and expenses, including, without limitation, fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions
contemplated hereby shall be paid by the Party incurring such costs and expenses.
                    SECTION
5.07 Binding Effect.   This Agreement shall become effective when it shall have been executed by the Parties and thereafter shall be binding upon and inure to the benefit of the Parties and their respective successors and assigns,
except that the Issuers shall not have the right to assign its rights hereunder or any interest herein without the prior written consent of the Purchaser.
                    SECTION 5.08   Survival.   The representations, warranties, covenants and agreements
made herein and in connection with the issuance of any Note shall survive any investigation made by Purchaser and the closing of the transactions contemplated hereby.
                    SECTION 5.09   Severability.   If any term or other provision of this Agreement is
invalid, illegal or incapable of being enforced by any Law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect for so long as the economic or legal substance of the transactions
contemplated by this Agreement is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to
modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions contemplated by this Agreement are consummated as originally contemplated to the greatest extent
possible.
                    SECTION 5.10   Entire Agreement.   The Transaction
Documents constitute the entire agreement of the Parties with respect to the subject matter hereof and thereof and supersede all prior agreements and undertakings, both written and oral, among the Parties with respect to the subject matter hereof
and thereof.
                    SECTION 5.11   No Third Party Beneficiaries.   This
Agreement shall be binding upon and inure solely to the benefit of the Parties and their permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy
of any nature whatsoever.
                    SECTION 5.12   Governing Law; Jurisdiction and
Enforcement.   This Agreement shall be governed by the Laws of the State of New York. All actions and proceedings arising out
 8

  of or relating to this Agreement shall be heard and determined in any New York state or federal court sitting in the City of New York. The Parties hereto hereby
(a) submit to the exclusive jurisdiction of any state or federal court sitting in The City of New York for the purpose of any action arising out of or relating to this Agreement brought by any Party hereto and (b) irrevocably waive, and
agree not to assert by way of motion, defense, or otherwise in any such action, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the
action is brought in an inconvenient forum, that the venue of the action is improper, or that this Agreement may not be enforced in or by any of the above-named courts.
                    SECTION 5.13   Dispute Resolution.   Except to the limited extent necessary to
obtain interim relief, including injunctive relief, to preserve the status quo or prevent irreparable harm, neither Party shall file an action or institute legal proceedings with respect to any dispute, controversy, or claim arising out of this
Agreement or the validity, interpretation, breach or termination thereof, including claims seeking redress or asserting rights under any Law, until:

		
	 	         (i)         the aggrieved Party has given the other Party written notice (“Notice of Disagreement”), in
accordance with Section 5.03 of this Agreement, of its grievance setting forth the basis for such dispute and the remedy desired;

 

		
	 	         (ii)         the other Party has failed to provide a prompt and effective remedy (in the view of the aggrieved
Party);

 

		
	 	         (iii)         the aggrieved Party has requested in writing senior executives for both Parties to promptly meet and discuss the
matter detailed in the Notice of Disagreement in order to consider informal and amicable means of resolution; and

 

		
	 	         (iv)         (a)   the senior executives for both Parties have met at least three times and have not been able to
resolve the dispute to the mutual satisfaction of the Parties or (b) more than sixty (60) business days have passed since the date of the Notice of Disagreement.

 
                    SECTION 5.14   Counterparts.   This Agreement may be executed and delivered
(including by facsimile transmission) in one or more counterparts, and by the different Parties in separate counterparts, each of which when executed shall be deemed to be an original, but all of which taken together shall constitute one and the
same agreement. Delivery of an executed counterpart of a signature page to this Agreement by facsimile shall be effective as delivery of a manually executed counterpart of this Agreement.
                    SECTION 5.15   Waiver of Jury Trial.   The Parties hereby knowingly, voluntarily and
irrevocably waive all right to trial by jury in any action, proceeding or counterclaim (whether based on contract, tort or otherwise) arising out of or relating to this Agreement or any course of conduct, course of dealing or statements (whether
oral or written) or actions of the Purchaser in the negotiation, administration, performance or enforcement thereof.
 [Signature Page Follows]
 9

                     IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to
be executed by their respective officers thereunto duly authorized, as of the date first above written.

				
		 		 
	 	CORAUTUS GENETICS INC.	 
	 	as Issuer	 
	 	 	 	 
	 	By:	/s/ RICHARD E. OTTO	 
	 	 	
	 
	 	Title:	Chief Executive Officer	 
	 	 	 	 
	 	VASCULAR GENETICS INC.	 
	 	as Issuer	 
	 	 	 	 
	 	By:	/s/ RICHARD E. OTTO	 
	 	 	
	 
	 	Title:	Chief Executive Officer	 
	 	 	 	 
	 	 	 	 
	 	BOSTON SCIENTIFIC CORPORATION	 
	 	as Purchaser	 
	 	 	 	 
	 	By:	/s/ LAWRENCE C. BEST	 
	 	 	
	 
	 	Title:	Senior Vice President &	 
	 	 	Chief Financial Officer	 

 10

  EXHIBIT A
FORM OF SENIOR CONVERTIBLE PROMISSORY NOTE

  EXHIBIT B
 FORM OF NOTICE OF BORROWING

  EXHIBIT C
 FORM OF OPINION OF COUNSEL TO THE COMPANYDevelopment Agreement

Table of Contents

 Exhibit 10.4
 DEVELOPMENT AGREEMENT
 by and
between
 BOSTON SCIENTIFIC CORPORATION
 and
 CORAUTUS GENETICS INC.

Dated as of July 30, 2003

Table of Contents

 
TABLE OF CONTENTS

	 	 	 
	 	 	Page 
		 ARTICLE I
 	 
	                                    
       	 DEFINITIONS
 	 
	 	 	 
	SECTION 1.01.	
General	 1
 
	SECTION 1.02.	
Additional Definitions	 4
 
	 	 	  
 
	  	 ARTICLE II
 	  
 
	 	 PRODUCT DEVELOPMENT
 	  
 
	 	 	  
 
	SECTION 2.01.	
Clinical Trials	 5
 
	SECTION 2.02.	
Clinical Plan	 5
 
	SECTION 2.03.	
Development of Final Products	 6
 
	SECTION 2.04.	
Regulatory Filings and Approvals	 6
 
	SECTION 2.05.	
Final Product Specifications	 6
 
	SECTION 2.06.	
Supply of VEGF-2	 7
 
	SECTION 2.07.	
Protocol Development	 7
 
	SECTION 2.08.	
Use of Injection Catheter	 7
 
	SECTION 2.09.	
License to the Company	 8
 
	SECTION 2.10.	
Supply and Support of Injection Catheters	 8
 
	SECTION 2.11.	
Reference Rights	 9
 
	SECTION 2.12.	
Representative	 9
 
	SECTION 2.13.	
Training Advice and Assistance	 9
 
	SECTION 2.14.	
Reporting Obligations	 9
 
	SECTION 2.15.	
Discovery and Development of New Products	 10
 
	SECTION 2.16.	
Exclusivity	 10
 
	 	 	  
 
	       	ARTICLE III	  
 
	 	INTELLECTUAL PROPERTY OWNERSHIP	  
 
	 	 	  
 
	SECTION 3.01.	
Pre-Existing Rights	 11
 
	SECTION 3.02.	
Joint Inventions by Both Parties	 11
 
	SECTION 3.03.	
New Inventions by Either Party	 11
 
	SECTION 3.04.	
Ownership of Injection Catheter Inventions and VEGF Inventions	 11
 
	 	 	 
	       	 ARTICLE IV
 	 
	 	 REPRESENTATIONS AND WARRANTIES
 	 
	 	 	 
	SECTION 4.01.	
Mutual Representations	 11
 
	SECTION 4.02.	
DISCLAIMER	 12
 
	SECTION 4.03.	
Company Warranties	 12
 
	SECTION 4.04.	
BSC Warranties	 12
 

 i

Table of Contents

			
	                           	 ARTICLE V
 	 
	   	INDEMNIFICATION AND INSURANCE	 
	 	 	 
	SECTION 5.01.	
Company Indemnity	13
	SECTION 5.02.	
BSC Indemnity	13
	SECTION 5.03.	
Indemnification Procedure	13
	SECTION 5.04.	
Limitation of Liability	14
	SECTION 5.05.	
Insurance	14
	SECTION 5.06.	
No Improper Representations or Warranties	14
	 	 	 
	 	 	 
	 	 ARTICLE VI
 	 
	 	 CONFIDENTIALITY
 	 
	 	 	 
	SECTION 6.01.	
Confidentiality	15
	SECTION 6.02.	
Release from Restrictions	15
	SECTION 6.03.	
Public Announcements and Publications	15
	 	 	 
	 	 	 
	 	 ARTICLE VII
 	 
	 	 TERM AND TERMINATION
 	 
	 	 	 
	SECTION 7.01.	
Expiration	16
	SECTION 7.02.	
Termination for Cause	16
	SECTION 7.03.	
Survival	16
	 	 	 
	 	 	 
	 	ARTICLE VIII	 
	 	MISCELLANEOUS	 
	 	 	 
	SECTION 8.01.	
Notices	16
	SECTION 8.02.	
Headings	17
	SECTION 8.03.	
Severability	17
	SECTION 8.04.	
Entire Agreement	18
	SECTION 8.05.	
Assignment	18
	SECTION 8.06.	
No Third Party Beneficiaries	18
	SECTION 8.07.	
Change of Control	18
	SECTION 8.08.	
Amendment	18
	SECTION 8.09.	
Governing Law and Venue	18
	SECTION 8.10.	
Dispute Resolution	18
	SECTION 8.11.	
Counterparts	19
	SECTION 8.12.	
No Waiver	19
	SECTION 8.13.	
Independent Contractor	19
	SECTION 8.14.	
Registration and Filing of this Agreement	19

 ii

Table of Contents

		
	Exhibits	 
	Exhibit A	
Clinical Plan
	Exhibit B	
Initial Forecast of BSC’s VEGF-2 Requirements
	Exhibit C	
Material Transfer Agreement (VEGF-2)
	Exhibit D	
Material Transfer Agreement (Injection Catheters)

 iii

Table of Contents

 DEVELOPMENT AGREEMENT
                    This DEVELOPMENT AGREEMENT (this “Agreement“) is made and entered into this 30th day
of July, 2003 (the “Effective Date”) by and between BOSTON SCIENTIFIC CORPORATION (“BSC”), a Delaware corporation, and CORAUTUS GENETICS INC. (the “Company”), a Delaware corporation (each a
“Party,” and collectively, the “Parties”).
 W I T N E S S E T H:
                    WHEREAS, the Parties are parties to the Investment Agreement, the Sublicense Agreement, the Distribution
Agreement (the “Distribution Agreement”), the Loan Agreement (the “Loan Agreement”) and the Investor Rights Agreement, each of even date herewith (collectively with this Agreement, the “Transaction
Documents”); and
                    WHEREAS, pursuant to the transactions contemplated by the
Transaction Documents, the Parties wish to cooperate to develop products that use VEGF-2 for the treatment of diseases of the heart or peripheral vascular system.
                    NOW, THEREFORE, in consideration of the premises and the mutual representations, agreements and covenants set
forth herein and in the other Transaction Documents, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
 ARTICLE I 
 DEFINITIONS
                     SECTION 1.01. 
General. As used herein, the following terms shall have the following meanings:

		
	 	          “Act” means the United States Food, Drug and Cosmetic Act and similar Laws in foreign jurisdictions, all as may be amended from time to
time, to the extent applicable.

 

		
	 	          “AE” means, with respect to use of any Product or Injection Catheter, any adverse event (within the meaning of applicable FDA regulations,
and including, without limitation, any unfavorable and unintended sign (including, without limitation, an abnormal laboratory finding), exacerbation of a pre-existing condition, intercurrent illness, drug interaction, significant worsening of a
disease under investigation or treatment, significant failure of expected pharmacological or biological action, or symptom or disease temporally associated with the use of such Product or Injection Catheter, whether or not considered to be related
to such Product or Injection Catheter), which event is associated with the use of such Product or Injection Catheter (i) in clinical investigation; or (ii) by a patient once such Product or Injection Catheter has been approved, whether or not such
event is considered to be drug-related. AE(s) shall include such events (i) occurring in the course of the use of such Product or Injection Catheter in professional practice; (ii) occurring from drug overdose whether accidental or
intentional;

Table of Contents

	 	 
	 	(iii) occurring from drug abuse; (iv) occurring from drug withdrawal; and (v) any significant and consistent failure of expected pharmacological action. Notwithstanding the foregoing, AEs shall include any experience
required to be reported to a relevant authority in any such country.

 

		
	 	          “Affiliate” means, with respect to any specified Person, any Person that, directly or indirectly, through one or more intermediaries,
controls, is controlled by, or is under common control with such specified Person.

 

		
	 	          “Approvals” means authorizations granted to the Company from a Regulatory Authority, including BLA approvals, to distribute, for either
investigational or commercial purposes, a medical drug or product.

 

		
	 	          “BLA” means a Biologics License Application filed with the FDA in respect of a Principal Product in order to manufacture, market, sell or
use the Principal Product in the United States.

 

		
	 	          “BSC Indemnitee” means BSC, its Affiliates, University of Michigan, HHMI, and each of their respective directors, officers, employees,
regents, trustees, fellows and agents.

 

		
	 	          “BSC Patents” means **

 

		
	 	          “Business Day” means any day that is not a Saturday, a Sunday or any other day on which banks are required or authorized by Law to be
closed in The City of New York.

 

		
	 	          “Company Indemnitee” means the Company, its Affiliates, and each of their respective directors, officers, employees and agents.

 

		
	 	          “Confidential Information” means all nonpublic proprietary information and materials (whether or not patentable), disclosed by one Party
(the “Disclosing Party”) to the other Party (the “Receiving Party”), irrespective of the manner in which the Disclosing Party disclosed such information and regardless of whether such information is labeled as
confidential, in furtherance of this Agreement, including, but not limited to, trade secrets under applicable Law, substances, formulations, techniques, methodology, equipment, data, reports, correspondence, know-how, manufacturing documentation and
sources of supply, as well as the terms of this Agreement.

 

		
	 	          “DMF” means the Drug Master File with respect to the Product or the Device Master File with respect to the Injection Catheter, as
applicable, filed with the FDA.

 

		
	 	          “FDA” means the United States Food and Drug Administration.

 

		
	 	          “Final Product” means, with respect to any Principal Product and country, the version of the relevant Principal Product that is approved by
a Regulatory Authority for marketing, distribution or sale in the relevant country.

 _________
 “***” indicates redacted confidential information pursuant to a confidential treatment request filed with the SEC. 
 2

Table of Contents

		
	 	          “Indemnified Party” means a Person seeking indemnification from a Party pursuant to and in accordance with the terms and conditions of this
Agreement.

 

		
	 	          “Indemnifying Party” means the Party from whom an Indemnified Party seeks indemnification pursuant to and in accordance with the terms and
conditions of this Agreement.

 

		
	 	          “Injection Catheter” means the injection catheter known as the StilettoTM manufactured by BSC, including improvements, modifications
and replacements thereto.

 

		
	 	          “Injection Catheter Invention” means Inventions relating solely to the Injection Catheter, including but not limited to manufacturing or
use thereof.

 

		
	 	          “Intellectual Property” means all intellectual property rights, including without limitation (i) United States and foreign patents and
patent applications, divisions, continuations, continuations-in-part, reissues, renewals, reexaminations, requests for continued examination, supplemental registrations or extensions thereof, (ii) trademarks, whether registered or unregistered
and applications for registration thereof, (iii) copyrights, whether registered or unregistered and applications for registration thereof, and (iv) trade secrets, know-how, technology, proprietary information and data, including, without
limitation, formulae, procedures, plans, methods, processes, specifications, models, protocols, techniques and experimentation, and design, testing and manufacturing data, and products, compositions, and procedures.

 

		
	 	          “Inventions” means findings, discoveries, inventions, additions, modifications, formulations, variations, enhancements, refinements or
derivative works.

 

		
	 	          “Law” means the Act and any other United States or non-United States federal, national, supranational, state, provincial, local or similar
statute, law, ordinance, regulation, rule, code, order, requirement or rule of law, to the extent applicable.

 

		
	 	          “Losses” means any losses, liabilities, claims asserted, awards, interest, judgments, penalties, expenses (including, without limitation,
reasonable attorneys’ fees and expenses), costs or damages.

 

		
	 	          “Person” means an individual, partnership, joint venture, corporation, limited liability company, trust, unincorporated organization or
other entity (including, without limitation, any “group” within the meaning of Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934).

 

		
	 	          “Principal Product” means a Product delivered via an injection catheter or hypodermic needle. By way of example, “Principal
Product” does not include a Product that is delivered via a coated stent or any device other than an injection catheter or hypodermic needle.

 

		
	 	          “Product” means a plasmid DNA, drug, biologic or other composition comprising VEGF-2 used for treatment of diseases of the heart or
peripheral vascular system; provided, however, “Product” does not include any delivery device (including without

 3

Table of Contents

	 	 
	 	 limitation the Injection Catheter, a hypodermic needle or stent) or the combination of any such plasmid DNA, drug, biologic or other composition with any such delivery device.
 

		
	 	          “Product Specifications,” for a Principal Product, means those specifications and performance requirements for such Principal Product as
mutually agreed by the Parties in accordance with Section 2.05 of this Agreement, including, without limitation, clinical, manufacturing and marketing specifications.

 

		
	 	          “Regulatory Authority” means the FDA and any other national, supra-national, regional, state or local regulatory agency, department,
bureau, commission, council or other governmental entity.

 

		
	 	          “Regulatory Filings” means, for any country, the regulatory documents necessary or advisable to be filed with a Regulatory Authority in
order to obtain all Approvals required for the importation, exportation, promotion, pricing, marketing or sale of the Principal Products in such country.

 

		
	 	          “VEGF-2” means the Human Genome Sciences angiogenic agent licensed to and being further developed and modified by the Company, sometimes
referred to as Vascular Endothelial Growth Factor 2 plasmid DNA, and any modifications or improvements thereto.

 

		
	 	          “VEGF Invention” means Inventions relating solely to VEGF-2, including but not limited to manufacturing or use thereof.

 
                       SECTION 1.02. 
Additional Definitions. The following terms have the meanings set forth in the Sections set forth below:

			
	Definition
	 	Location

	Agreement	 	Preamble
	BSC	 	Preamble
	BSC Representative Group	 	2.12
	Clinical Developments	 	2.01
	Clinical Plan	 	2.02
	Company	 	Preamble
	Company Representative Group	 	2.12
	Distribution Agreement	 	Recitals
	Effective Date	 	Preamble
	HHMI	 	2.09(c)
	Joint Invention	 	3.02
	Loan Agreement	 	Recitals
	Michigan License	 	2.09(b)
	Notice of Disagreement	 	8.10
	Parties	 	Preamble
	Party	 	Preamble
	Plan Modifications	 	2.02

 4

Table of Contents

			
	Definition
	 	Location

	Representatives	 	2.12
	Term	 	7.01
	Transaction Documents	 	Recitals
	University of Michigan	 	2.09(b)

 ARTICLE II 
 PRODUCT DEVELOPMENT
                  SECTION 2.01.  
Clinical Trials.  In accordance with the Clinical Plan, the Company shall develop the design and shall sponsor human clinical trials for the Principal Products, including the research and development activities
described in the Clinical Plan, the development of clinical protocol, clinical evaluation site selection, clinical patient selection, clinical trial management, and Phase II efficacy research testing and beyond (collectively, the “Clinical
Developments”). The objective of the Clinical Developments is to generate data required to obtain Approvals from the FDA and other relevant Regulatory Authorities to market, distribute and sell the Principal Products.
                  SECTION 2.02.  
Clinical Plan.  (a)  Attached hereto as Exhibit A is the initial research and development plan setting forth activities, schedules, milestones, specifications, pre-clinical and clinical protocols
and requirements for development of the Principal Products (the “Clinical Plan”). The Company may, from time to time, adopt or institute amendments, supplements and variations (collectively, “Plan Modifications”) to
the Clinical Plan; provided, however, (i) the Company shall provide the BSC Representative Group with a copy of all such Plan Modifications and (ii) any Plan Modifications that would materially alter the then current version of the
Clinical Plan may only be made in accordance with paragraphs (b) and (c) below.
                  (b)    With respect to Plan Modifications that would materially alter the then current version of the
Clinical Plan, the BSC Representative Group shall have an opportunity to review and, except as provided in paragraph (c) below, approve or reject such Plan Modifications; provided, however, the BSC Representative Group shall not
unreasonably withhold or delay approval of such Plan Modifications, and if the BSC Representative Group has not rejected such Plan Modifications within forty five (45) days of receiving a copy of such Plan Modifications then the BSC Representative
Group will be deemed to have accepted such Plan Modifications; provided, further, the Parties acknowledge and agree that it is not unreasonable for the BSC Representative Group to reject any Plan Modifications if BSC, in its sole
discretion, believes such Plan Modifications will have a material deleterious effect on BSC’s ability to market or distribute the Injection Catheter. In the event that the BSC Representative Group rejects such Plan Modifications, the
Representatives shall have thirty (30) days to work together to revise such Plan Modifications. If the Representatives cannot agree on such Plan Modifications then, notwithstanding anything herein to the contrary, the Company may proceed with the
Clinical Plan, as modified by the Company in its sole discretion; but BSC shall have no further obligation to supply Injection Catheters pursuant to Section 2.10 of this Agreement, and the Company shall return to BSC any and all Injection Catheters
in its possession or within its control.
 5

Table of Contents

                     (c)         Notwithstanding
paragraph (b) above, in the event any Plan Modifications to the Clinical Plan are required by the FDA or other relevant Regulatory Authorities, such Plan Modifications may be made by the Company without the approval of the BSC Representative Group,
and BSC shall continue to have the obligation to supply Injection Catheters pursuant to Section 2.10 of this Agreement.
                     SECTION 2.03.  
Development of Final Products.   The Company shall use its commercially reasonable efforts to develop the Final Products in accordance with the schedule set forth in the Clinical Plan and complete Clinical
Development of the Final Products in accordance with the following schedule:
                                     
          ***
                     SECTION 2.04.
  
Regulatory Filings and Approvals.  The Company shall be the sponsor of and will own the FDA applications for the Principal Products; provided, however, that the Company shall consider and in good
faith endeavor to incorporate all comments and proposals made thereto by BSC, and shall incorporate all comments to the extent that they relate to the Injection Catheters. BSC shall be responsible for (a) all contributions to Regulatory Filings
relating to the Injection Catheters and (b) all costs arising from its comments relating primarily to the development of the Injection Catheters. The Company, at its expense, and in accordance with the Clinical Plan, shall be responsible for making
all other contributions for, undertaking, completing and obtaining, all Regulatory Filings for each Principal Product. The BLA for the Principal Products shall be submitted in the Company’s name. The Company shall devote commercially reasonable
efforts to undertake, complete and obtain all Approvals for the Principal Products in the United States and in each other jurisdiction where the Parties mutually agree to pursue Approvals for the Principal Products. The Parties acknowledge that
there is no assurance that Approvals for any Principal Product will be obtained in the United States or any other jurisdiction.
                     SECTION 2.05.  
Final Product Specifications.   As the Parties progress toward the development of the Final Products, the marketing personnel from both Parties, with consultation from the clinical, regulatory and research and
development personnel of both Parties, shall work together to develop Product Specifications for the Final Products. The Representatives shall be responsible for approving Product Specifications for such Final Products, which Product Specifications,
once approved by the Representatives, may not be amended without the prior written consent of BSC; provided, however, in the event any modifications to the Product Specifications are required by the FDA or other relevant Regulatory
Authorities, such modifications to the Plan Specifications may be made by the Company without the consent of
 _________
 “***” indicates redacted confidential information pursuant to a confidential treatment request filed with the SEC. 
 6

Table of Contents

 BSC; provided, further, that a copy of such modifications are provided to BSC as soon as reasonably practicable.
                     SECTION 2.06.  
Supply of VEGF-2.   ***   BSC shall, on a quarterly basis, provide the Company with a six (6) month non-binding forecast of its VEGF-2 requirements for such studies. The Company shall ensure that it has
a sufficient supply of VEGF-2 to satisfy BSC’s forecasted needs for such studies. BSC’s initial forecast is attached hereto as Exhibit B and sets forth a date for delivery of the first shipment of VEGF-2 as one month from the
Effective Date. VEGF-2 for studies relating to the Principal Products shall be supplied pursuant to a Material Transfer Agreement, a form of which is attached hereto as Exhibit C; provided, however, that any terms in such
Material Transfer Agreement that are inconsistent with this Agreement shall be null and void. In the event BSC desires to obtain additional quantities of VEGF-2 from the Company for research related to Products other than the Principal Products, the
parties shall discuss in good faith the transfer of such VEGF-2 pursuant to a mutually agreeable Material Transfer Agreement.
                     SECTION 2.07.  
Protocol Development.   Each Party shall provide the other Party with access to the protocol for human clinical trials and pre-clinical animal trials of the Principal Products or Injection Catheter and access to
and use of the clinical trial data and results, in each case on an ongoing basis, solely for use in connection with seeking necessary Approvals for use of the Principal Product. The Representatives shall meet to discuss any comments and proposals
BSC has with respect to the protocol, and the Company Representative Group shall make a good faith endeavor to incorporate the comments and proposals made by BSC. To the extent that BSC’s comments and proposals relate to the Injection Catheter,
the Company shall incorporate all such comments and proposals into the protocol; provided, however, BSC shall be responsible for all costs arising from its comments relating primarily to the development of the Injection
Catheters.
                     SECTION 2.08.  
Use of Injection Catheter.
                     (a)
        The Company agrees that the Injection Catheters provided by BSC pursuant to this Agreement shall be used by the Company solely for endovascular injections in the human clinical trials conducted during
Clinical Development of the Principal Products. The Company further agrees that it will not, after the date of this Agreement, use any injection catheter other than the Injection Catheter in human clinical trials during Clinical Development of the
Principal Products without the prior written consent of BSC.
                     (b)
        The Company acknowledges and agrees that the Injection Catheters have not been approved by the FDA. Use by the Company of the Injection Catheters shall be in accordance with the training and instructions
provided by BSC pursuant to Section 2.13. Use of the Injection Catheters in humans shall only be pursuant to the Clinical Plan.
                     (c)         During the Term of this Agreement, no pre-clinical and
clinical studies organized, initiated, sponsored or conducted by the Company shall include the comparison of any device for the intramyocardial delivery of Principal Products with the Injection Catheters without the prior written consent of BSC. No
data collected or derived from any pre-clinical or clinical study conducted by the Company shall be commingled, pooled or in any way compared
 _________
 “***” indicates redacted confidential information pursuant to a confidential treatment request filed with the SEC. 
 7

Table of Contents

 to or presented in conjunction with data regarding any device other than the Injection Catheter without the prior written consent of BSC, which consent shall not be unreasonably
withheld; provided, however, that the consent of BSC shall not be required in the event such data is requested or required by the FDA or other applicable Regulatory Authority, but BSC shall, as soon as reasonably practicable, be
informed of any such requests or requirements by the FDA or other applicable Regulatory Authority.
                     SECTION 2.09.  
License to the Company.
                     (a)
        Subject to the terms and conditions set forth in this Agreement, BSC hereby grants the Company a nonexclusive, nonsublicensable, nontransferable, royalty-free license under BSC Patents during the Term to
make, have made and use the Products solely in connection with the Company’s development of Products in accordance with the terms and conditions of this Agreement. The Company acknowledges and agrees that (i) the foregoing license does not
cover the sale, distribution, importation, marketing or other commercial use of Products and (ii) unless otherwise agreed to by BSC in writing, any Products sold, transferred, given or otherwise provided to Persons other than BSC by the Company
(other than providing to Persons for research, testing and development purposes) violates this license grant and the terms of this Agreement.
                     (b)         The Parties acknowledge and agree that some of the BSC
Patents are owned by the Regents of the University of Michigan (the “University of Michigan”) and that the entire license (or a portion thereof) granted pursuant to Section 2.09(a) may be terminated by BSC upon the termination of
the license agreement entered into by Genocor, Inc., BSC and the Regents of the University of Michigan on June 17, 1997 (the “Michigan License”).
                     (c)         The Company agrees not to use the name of the University of
Michigan or Howard Hughes Medical Institute (“HHMI”) in publicity or advertising with respect to the Products without the prior written approval of the University of Michigan or HHMI.
                     (d)         The Parties acknowledge and agree that the University of
Michigan and HHMI make no warranty and shall not be held liable for any direct, indirect, special, incidental or consequential damage or lost profits or other economic loss or damage with respect to the BSC Patents or any Products.

                    (e)         To the extent allowed by the University of
Michigan and any other third party owners of the BSC Patents, as applicable, BSC shall use commercially reasonable efforts to prosecute, maintain and defend the BSC Patents.
                     SECTION 2.10.  
Supply and Support of Injection Catheters.  (a)  ***  The Company shall, on a monthly basis, provide BSC with a six (6) month forecast of its Injection Catheter requirements; provided,
however, that, unless the Parties mutually agree otherwise, (1) the Company may not request more than *** Injection Catheters, excluding Injection Catheters required for training and defective Injection Catheters, through Phase IIb trials,
and (2) after Phase IIb trials, the Company may not request more than *** Injection Catheters per eight month period. The Injection Catheters for such studies shall be supplied pursuant to a Material Transfer Agreement, a form of which is attached
hereto as Exhibit D; provided, however, that any terms
 _________
 “***”
indicates redacted confidential information pursuant to a confidential treatment request filed with the SEC. 
 8

Table of Contents

 in such Material Transfer Agreement that are inconsistent with this Agreement shall be null and void. BSC shall ensure that it has a sufficient supply of Injection Catheters to satisfy
the Company’s forecasted needs.
                    (b)         BSC
shall use commercially reasonable efforts to assist in all clinical and regulatory activities necessary or useful to support the use of Injection Catheters in the protocol for human clinical trials of Principal Products and achieve Approvals for use
of the Injection Catheter as a delivery vehicle for the Principal Products.
                     SECTION
2.11.  
Reference Rights.  BSC and the Company shall each have reference rights to the other Party’s DMF filed at the FDA with respect to Products and Injection Catheters.
                     SECTION 2.12.  
Representative.  To oversee the progress of the Clinical Development and the manufacture of the Principal Products, the Company and BSC shall appoint one or more representatives each (the “Company
Representative Group” and the “BSC Representative Group,” respectively, and together, the “Representatives”). The Representatives shall meet in person or via teleconference monthly to discuss the progress
of the Clinical Development and the manufacture of the Principal Products.
                     SECTION
2.13.  
Training Advice and Assistance.  BSC shall provide reasonable technical assistance and training to the Company and its investigators regarding the usage of Injection Catheter supplied to the Company. BSC shall,
at its cost, provide such assistance and training at a reasonable number of clinical sites, not to exceed twenty (20) sites.
                     SECTION 2.14.  
Reporting Obligations.  (a)    Quarterly Reports.  The Company shall provide BSC with a written quarterly report on the progress of the development of the Principal Products, and
such report shall be in a form mutually agreed upon by the Representatives.
                     (b)
        Adverse Events and Product Complaints.   Each Party shall (i) adhere to all requirements of applicable Laws which relate to the reporting and investigation of AEs anywhere in the world and
keep the other Party informed of such matters, (ii) promptly inform the other Party of any material safety or health incidents related to any Final Product or Injection Catheter, including the use, manufacture, labeling or packaging of any of the
foregoing, and (iii) promptly inform the other Party upon becoming aware of any unusual or unexpected reactions or events, malfunctions, safety or efficacy of or attributable to any Product or VEGF-2 or Injection Catheter and/or any Regulatory
Authority action related thereto.
                     (c)        
Exchange of Drug Safety Information.   Each Party shall immediately provide the other Party with drug or device safety requests from all governmental and other Regulatory Authorities. Proposed answers affecting a Product or
Injection Catheter will be exchanged with the other Party before submission, and the Parties shall cooperate with respect to such answers; provided, however, that the Company shall have the ultimate decision making authority with
respect to answers relating to the Products, and BSC shall have the ultimate decision making authority with respect to answers relating to the Injection Catheters. Each Party
 9

Table of Contents

 shall provide the other Party the decisions received from the applicable Regulatory Authorities reasonably promptly after the Party receives notice of such decision.
                     (d)         Regulatory Actions.  Each Party shall advise
the other Party of any regulatory action of which it is aware which would affect any Product in any country.
                     (e)         Governmental Inspection. Each Party shall
advise the other Party of any governmental communication, inspection or report or Law relating to a Product or Injection Catheter of which it is aware and which might reasonably be expected to affect the Principal Product or Injection Catheter. Any
response to a regulatory notice relating to the Principal Products, Injection Catheters or such Law shall be prepared jointly by the Parties, with the lead role taken by the Party to whom such notice is addressed (or, if addressed to both Parties,
with the lead role taken by the Company unless the notice relates to the Injection Catheter in which case BSC shall take the lead role); provided, however, that each Party shall be entitled to take all such actions with respect to such
notice as are required of it by Law. Both Parties shall have the right to be present during any such inspection.
                     SECTION  2.15.  
Discovery and Development of New Products.  (a)  The Parties shall cooperate with each other in creating improvements to the Principal Products and new product developments for cardiovascular applications
using VEGF-2. If either Party discovers any new product for cardiovascular applications (including Products other than Principal Products) or creates improvements to the Principal Products during the Term of this Agreement, that Party shall present
such new developments or improvements to the other Party and the Parties shall, in good faith, discuss the possibility of jointly funding and developing such new developments or improvements. Notwithstanding the foregoing, neither Party shall be
under any obligation to fund, develop, co-develop or in any way pursue funding or development of any new developments, improvements or products (including Products other than Principal Products).
                     (b)         In the event the Parties choose to jointly develop a new
improvement or product, the Parties shall either revise this Agreement to provide for such development or enter into another agreement regarding the development of such improvement or product.
                     SECTION  2.16.  
Exclusivity.  Notwithstanding anything in this Agreement to the contrary, during the Term of this Agreement, the Company may not enter into any development, distribution or similar agreement with respect to the
Principal Products (excluding clinical site agreements, manufacturing agreements, contract research agreements and other agreements necessary or useful for the clinical testing of the Principal Products) with Persons other than BSC without the prior
written consent of BSC. Subject to the Company’s obligations to first discuss development of Products with BSC pursuant to Section 2.15 and BSC’s right to distribute Products pursuant to the Distribution Agreement, the Company may enter
into development, testing and similar arrangements with respect to Products other than Principal Products with Persons other than BSC without the prior written consent of BSC.
 10

Table of Contents

 ARTICLE III 
 INTELLECTUAL PROPERTY OWNERSHIP
                     SECTION  3.01.  
Pre-Existing Rights.  Each Party acknowledges that any and all Intellectual Property of the other Party is and shall continue to be owned by such other Party, subject only to the licenses granted.
                     SECTION  3.02.  
Joint Inventions by Both Parties.  If an Invention, other than an Injection Catheter Invention or VEGF Invention, is conceived, discovered or reduced to practice jointly by both Parties pursuant to performance
under this Agreement (a “Joint Invention”), the Parties agree to reasonably assist each other in obtaining patent protection for such Joint Invention. Such Joint Inventions shall be jointly owned by the Parties without any right or
duty of accounting. Expenses relating to any patent applications covering Joint Inventions shall be shared equally by the Parties. If either Party elects not to file or maintain any such application or patent issuing from such application in any
country, then that Party shall promptly notify the other Party who then shall have the right to file or maintain such application or patent in its own name and at its sole expense.
                     SECTION  3.03.  
New Inventions by Either Party.  Each Party shall retain all right, title and interest in any and all Intellectual Property in and to Inventions, other than Injection Catheter Inventions and VEGF Inventions,
conceived, discovered or reduced to practice solely by that Party pursuant to performance under this Agreement.
                     SECTION  3.04.  
Ownership of Injection Catheter Inventions and VEGF Inventions.  Notwithstanding anything herein to the contrary, regardless of which Party discovered or reduced to practice any Injection Catheter Invention or VEGF
Invention: (i) BSC shall own all right, title and interest in and to all Injection Catheter Inventions, and the Company hereby assigns to BSC all of its right, title and interest in and to such Injection Catheter Inventions and agrees to execute any
documents necessary to record or otherwise perfect such assignment; and (ii) the Company shall own all right, title and interest in and to all VEGF Inventions, and BSC hereby assigns to the Company all of its right, title and interest in and to such
VEGF Inventions and agrees to execute any documents necessary to record or otherwise perfect such assignment.
 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES
                     SECTION  4.01.  
Mutual Representations.   Each Party hereby represents and warrants to the other Party as follows:
                     (a)         The execution, delivery and performance of this Agreement
by such Party have been duly authorized by all necessary action on the part of such Party.
                     (b)         This Agreement has been duly executed and delivered by such
Party and, assuming due authorization, execution and delivery by the other Party, constitutes a legal, valid and binding obligation of such Party, enforceable against such Party in accordance with its terms, 
 11

Table of Contents

 subject to (i) the effect of any applicable bankruptcy, insolvency, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights and remedies
generally, and (ii) the effect of general equitable principles, regardless of whether asserted in a proceeding in equity or at law.
                     (c)         Such Party’s execution, delivery and performance of
this Agreement and the consummation of the transactions contemplated hereby does not and will not (i) violate, conflict with or result in the breach of any provision of the certificate of incorporation or by-laws (or similar organizational
documents) of such Party, (ii) conflict with or violate any Law or governmental order applicable to such Party or its assets, properties or businesses, or (iii) conflict with, result in any breach of, constitute a default (or event which with the
giving of notice or lapse of time, or both, would become a default) under, require any consent under, or give to others any rights of termination, amendment, acceleration, suspension, revocation or cancellation of, or result in the creation of any
encumbrance on any of its outstanding shares of common stock or preferred stock or any of the assets or properties of such Party pursuant to, any note, bond, mortgage or indenture, contract, agreement, lease, sublease, license, permit, franchise or
other instrument or arrangement to which it is a party or by which any of such Party’s shares of common stock or preferred stock or any of the Party’s assets or properties is bound or affected.
                     (d)         It is not a party to any litigation relating to, or that
could reasonably be expected to affect, its ability to perform its obligations under this Agreement.
                     SECTION  4.02.  
DISCLAIMER.   EXCEPT AS EXPLICITLY PROVIDED IN THIS ARTICLE, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND, EXPRESS, IMPLIED, OR STATUTORY, AND THE PARTIES EXPRESSLY DISCLAIM ALL OTHER WARRANTIES,
INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
                     SECTION  4.03.  
Company Warranties.   (a)   The Company hereby represents and warrants that, to the actual knowledge of the Company, the development and use of Principal Products does not infringe, misappropriate, dilute or
otherwise violate the Intellectual Property of any third party.
                     (b)
        The Company represents and warrants that it is not party to, and will not enter into, any development, design or similar agreement with respect to the Principal Products (excluding clinical site agreements,
manufacturing agreements, contract research agreements and other agreements necessary or useful for the clinical testing of the Principal Products) with any Person other than BSC without the prior written consent of BSC.
                     SECTION  4.04.  
BSC Warranties.   (a)   BSC represents and warrants that it has the right to grant the license set forth in Section 2.09(a) of this Agreement.
                     (b)         BSC represents and warrants that the BSC Patents have not
been adjudged invalid or unenforceable and, to the actual knowledge of BSC, are not subject to any outstanding consent, settlement, decree, order, injunction, judgment or ruling that would impair the validity or enforceability of the BSC
Patents.
 12

Table of Contents

                     (c)         BSC represents and
warrants that, to the actual knowledge of BSC, the development, manufacture and use of the Injection Catheter does not infringe, misappropriate, dilute or otherwise violate the Intellectual Property of any third party.
 ARTICLE V
 INDEMNIFICATION AND INSURANCE
                     SECTION  5.01.  
Company Indemnity.   The Company shall indemnify, defend and hold harmless each BSC Indemnitee from any and all Losses actually suffered or incurred by BSC arising out of or resulting from: (a) the breach of any
representation or warranty, covenant or agreement by the Company contained in this Agreement, provided, for purposes of determining whether there is a breach of the representation and warranty set forth in Section 4.03(a), the knowledge
qualifier shall be disregarded; (b) any negligent act or omission or willful misconduct of the Company in connection with performance of its obligations under this Agreement; (c) the design, manufacture, use or administration of a Principal Product,
except to the extent attributable to the Injection Catheter or the negligent act or omission or willful misconduct of BSC or its officers, agents or employees; and (d) injury, illness, death or property damage in connection with the Principal
Products or clinical trials contemplated by this Agreement, except to the extent attributable to the Injection Catheter or the negligent act or omission or willful misconduct of BSC or its officers, agents or employees.
                     SECTION  5.02.  
BSC Indemnity.  BSC shall indemnify, defend and hold harmless each Company Indemnitee from any and all Losses actually suffered or incurred by the Company arising out of or resulting from: (a) the breach of any
representation or warranty, covenant or agreement by BSC contained in this Agreement, provided, for purposes of determining whether there is a breach of the representation and warranty set forth in Section 4.04(c), the knowledge qualifier
shall be disregarded; (b) any negligent act or omission or willful misconduct of BSC in connection with performance of its obligations under this Agreement; (c) the design, manufacture, use or administration of the Injection Catheter, except to the
extent attributable to the Principal Products or the negligent act or omission or willful misconduct of the Company or its officers, agents or employees; and (d) injury, illness, death or property damage caused by the Injection Catheter, except to
the extent attributable to the Principal Products or the negligent act or omission or willful misconduct of the Company or its officers, agents or employees.
                     SECTION  5.03.  
Indemnification Procedure.   (a)  Any Indemnified Party seeking indemnification under this Agreement shall give prompt written notice to the Indemnifying Party of any claim, assertion, event or proceeding by
or in respect of a third party of which such Indemnified Party has knowledge concerning any Losses as to which such Indemnified Party may request indemnification hereunder; provided, however, that the failure to provide or a delay in
providing such notice shall not release the Indemnifying Party from any of its obligations under this Agreement, except to the extent that the Indemnifying Party is actually prejudiced by such failure or delay, and shall not relieve the Indemnifying
Party from any other obligation or liability that it may have to any Indemnified Party otherwise than under this Agreement.
 13

Table of Contents

                     (b)          The Indemnifying Party shall have the right
to assume, through counsel of its own choosing, which counsel shall be reasonably satisfactory to the Indemnified Party, the defense or settlement of any claim or proceeding the subject of indemnification hereunder at its own expense, so long as the
Indemnifying Party first acknowledges in writing its obligation to indemnify the Indemnified Party hereunder against any and all Losses that may result from such claim or proceeding. If the Indemnifying Party elects to assume the defense of any such
claim or proceeding, the Indemnified Party may participate in such defense, but in such case the expenses of the Indemnified Party with respect to its assumption of such defense shall be borne and paid by the Indemnified Party. Notwithstanding the
foregoing, the Indemnified Party shall have the right to employ separate counsel at the Indemnifying Party’s expense and to control its own defense of any such claim or proceeding if a conflict or potential conflict exists between the
Indemnifying Party and the Indemnified Party that would make such separate representation advisable under applicable standards of professional conduct.
                    (c)          If the Indemnifying Party elects to assume
the defense of any claim or proceeding, no settlement in respect of any third-party claim may be effected by the Indemnifying Party without the Indemnified Party’s prior written consent, which consent shall not be unreasonably withheld or
delayed. If the Indemnifying Party fails to undertake any such defense, the Indemnified Party shall have the right to undertake the defense or settlement thereof at the Indemnifying Party’s expense. Notwithstanding anything herein to the
contrary, regardless of whether the Indemnifying Party has assumed the defense of any claim or proceeding pursuant to this Section 5.03, the Indemnified Party shall not settle any claim or proceeding without the prior written consent of the
Indemnifying Party, which consent shall not be unreasonably withheld or delayed; provided, however, that the Parties agree that it shall be reasonable for the Indemnifying Party to withhold its consent if any such settlement involves
any admission of liability or wrongdoing by the Indemnified Party or the Indemnifying Party.
                     SECTION 5.04.  
Limitation of Liability.  IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR RELATED TO THIS AGREEMENT, EXCEPT TO THE EXTENT SUCH DAMAGES: (A) ARE
INCLUDED IN AN AWARD AGAINST EITHER PARTY RESULTING FROM A THIRD PARTY CLAIM FOR WHICH SUCH PARTY IS INDEMNIFIED HEREUNDER; OR (B) ARE RELATED TO OR ARISE FROM WILLFUL OR INTENTIONAL MISCONDUCT.
                     SECTION 5.05.  
Insurance.  Effective sixty (60) days after the Effective Date and so long as the Company has any obligations under Article V of this Agreement, the Company shall maintain comprehensive general liability insurance,
including products liability, with a minimum liability coverage limit of ten million dollars ($10,000,000) per occurrence and naming BSC, University of Michigan and HHMI (including their regents, trustees, fellows, officers and employees) as
additional insureds. The Company shall provide BSC with a copy of a certificate of insurance evidencing compliance with this provision. Such certificate of insurance shall also provide BSC with thirty days’ prior written notice of cancellation,
modification or termination.
                      SECTION 5.06.  
No Improper Representations or Warranties.  Neither Party shall make any statements, representations or warranties or accept any liabilities or responsibilities that are inconsistent with any disclaimer or
limitation included in this Article V.
 14

Table of Contents

 ARTICLE VI
CONFIDENTIALITY
                     SECTION 6.01.  
Confidentiality.  During the Term of this Agreement and for the period of three (3) years thereafter, the Receiving Party shall maintain Confidential Information in confidence and shall not disclose, divulge or
otherwise communicate such Confidential Information to others, or use it for any purpose, except pursuant to, and in order to carry out, the terms and objectives of this Agreement. The Receiving Party hereby shall exercise every reasonable
precaution to prevent and restrain the unauthorized disclosure of such Confidential Information by any of its directors, officers, employees, consultants, subcontractors or agents. Upon termination of this Agreement, each Party shall return to the
other Party, upon demand, all Confidential Information in its possession or, upon demand, destroy such Confidential Information and provide a certificate to the other Party of such destruction signed by an officer of the destroying Party.

                    SECTION 6.02.  
Release from Restrictions.  The provisions of Section 6.01 shall not apply to any information disclosed hereunder that:

		
	 	          (a)           is lawfully disclosed to the Receiving Party by an independent, unaffiliated third party
rightfully in possession of the information and under no confidentiality or fiduciary obligation not to make disclosure;

 

		
	 	          (b)           becomes published or generally known to the public through no fault or omission on the part
of the Receiving Party;

 

		
	 	          (c)           is developed independently by the Receiving Party without access to the Confidential
Information of the Disclosing Party;

 

		
	 	          (d)           is legally required to be disclosed to a Regulatory Authority in the United States or in
another jurisdiction in which the Parties have agreed to seek Approvals; provided, however, the Receiving Party shall continue to treat such information as confidential pursuant to Section 6.01 unless and until such information becomes
published or generally known to the public through no fault or omission on the part of the Receiving Party; or

 

		
	 	          (e)           a Party is legally compelled to disclose; provided, however, that the
Receiving Party shall provide prompt written notice of such requirement to the Disclosing Party so that the Disclosing Party may seek a protective order or other remedy or waive compliance with Section 6.01; and provided further that
in the event such protective order or other remedy is not obtained or the Disclosing Party waives compliance with Section 6.01, the Receiving Party shall be permitted to furnish only that portion of such Confidential Information that is legally
required to be provided, and the Receiving Party shall exercise its reasonable best efforts to obtain assurances that confidential treatment shall be accorded such information.

 
                      SECTION 6.03.  
Public Announcements and Publications.  Except as required by Law or by the requirements of any securities exchange on which the securities of a Party hereto are listed, no Party shall make, or cause to be made,
any press release or public announcement in
 15

Table of Contents

 respect of this Agreement or the transactions contemplated hereby or otherwise communicate with any news media in respect of this Agreement or the transactions contemplated
hereby without the prior written consent of the other Party, and the Parties shall cooperate as to the timing and contents of any such press release or public announcement.
 ARTICLE
VII
TERM AND TERMINATION
                     SECTION 7.01.  
Expiration.  This Agreement shall remain in full force and effect until the termination or expiration of the Distribution Agreement (the “Term”), unless terminated earlier in accordance with this
Article VII.
                     SECTION 7.02.  
Termination for Cause.  (a)  This Agreement may be terminated by either Party if the other Party shall be in material breach of any provision contained in this Agreement and any such breach shall not have been
remedied within forty-five (45) Business Days after receipt of written notice from the terminating Party specifying (i) such breach and (ii) intention to terminate if such breach is not cured within forty-five (45) Business Days.
                     (b)          This Agreement may be terminated by the
Company in the event that BSC materially breaches the Loan Agreement and such breach shall not have been remedied within forty-five (45) Business Days after receipt of written notice from the Company specifying (i) such breach and (ii) intention to
terminate this Agreement if such breach is not cured within forty-five (45) Business Days.
                     (c)          This Agreement may also be terminated by
BSC following an Event of Default (as defined in the Senior Convertible Promissory Notes issued under the Loan Agreement).
                     SECTION 7.03.  
Survival.  In addition to any clause which by its express term survives termination or expiration, the respective rights and obligations of the Parties under the provisions of Articles III (Intellectual Property
Ownership), V (Indemnification and Insurance), VI (Confidentiality), VII (Term and Termination), and VIII (Miscellaneous) shall also survive any termination or expiration of this Agreement.
 ARTICLE VIII
MISCELLANEOUS
                     SECTION 8.01.
 
Notices.  All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given or made (and shall be deemed to have been duly given or made upon receipt) by delivery in
person, by an internationally recognized overnight courier service, by telecopy or registered or certified mail (postage prepaid, return receipt requested) to the respective Parties at the following addresses (or at such other address for a Party as
shall be specified in a notice given in accordance with this Section 8.01):
 16

Table of Contents

			
	 	(a) 	 if to the Company: 
 
 Corautus Genetics Inc. 
 430 Tenth Street, NW 
 Suite S-204 
 Atlanta, GA 30318 
 Telecopy: (404) 526-6218 
 Attention: Richard E. Otto, Chief Executive Officer 
 

with a copy to: 
 
 McKenna Long & Aldridge LLP 
 303 Peachtree Street, Suite 5300 
 Atlanta, GA 30308 
 Telecopy: (404) 527-4198 
 Attention: Robert E. Tritt

 

			
	 	(b) 	 if to BSC: 
 
 Boston Scientific Corporation 
 One Boston Scientific Place 
 Natick, MA 01760-1537 
 Telecopy: (508) 650 8956 
 Attention: Lawrence C. Best, Senior Vice President and CFO 
 

with a copy to: 
 
 Boston Scientific Corporation 
 One Boston Scientific Place 
 Natick, MA 01760-1537 
 Telecopy: (508) 650 8956 
 Attention: General Counsel

 
                     SECTION 8.02.  
Headings.  The descriptive headings contained in this Agreement are for convenience of reference only and shall not affect in any way the meaning or interpretation of the Agreement.
                     SECTION 8.03.  
Severability.  If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any Law or public policy, all other terms and provisions of this Agreement shall nevertheless
remain in full force and effect for so long as the economic or legal substance of the transactions contemplated by this Agreement is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision
is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner in order that the transactions
contemplated by this Agreement are consummated as originally contemplated to the greatest extent possible.
 17

Table of Contents

                    SECTION 8.04.  
Entire Agreement. The Transaction Documents constitute the entire agreement of the Parties with respect to the subject matter thereof and supersede all prior agreements and undertakings, both written and oral, among the
Parties with respect to the subject matter thereof.
                    SECTION 8.05.  
Assignment. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors and permitted assigns. Neither Party may assign this Agreement without the prior written
consent of the other Party; provided, however, that BSC may assign to an Affiliate its rights and obligations under this Agreement without the approval of the Company; provided further that no such assignment by BSC to an
Affiliate shall relieve BSC of any obligation or liability hereunder, whether then existing or thereafter incurred by BSC or its assignee. No assignment by either Party permitted hereunder shall relieve the applicable Party of its then-existing
obligations under this Agreement.
                    SECTION 8.06.   
No Third Party Beneficiaries. This Agreement shall be binding upon and inure solely to the benefit of the Parties and their permitted assigns, and nothing herein, express or implied, is intended to or shall confer upon any
other Person any legal or equitable right, benefit or remedy of any nature whatsoever.
                    SECTION 8.07.  
Change of Control. In the event of a change of control of the Company or BSC, this Agreement and all rights and obligations of each Party shall survive such change of control unaffected.
                    SECTION 8.08.  
Amendment. This Agreement may not be amended or modified except by an instrument in writing signed by authorized representatives of the Company and BSC. In the event the University of Michigan or any third party owner of a
BSC Patent requests that BSC amend the terms of this Agreement in order to comply with the Michigan License or the terms of the patent license agreements entered into by BSC and such third party owners, BSC and the Company shall discuss in good
faith the amending of this Agreement to incorporate the requested amendment.
                    SECTION
8.09.  
Governing Law and Venue. This Agreement shall be governed by, and construed in accordance with, the Laws of the State of New York. The Parties unconditionally and irrevocably agree and consent to the exclusive jurisdiction
of the courts located in the state of New York and waive any objection with respect thereto, for the purpose of any action, suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby, and further agree
not to commence any such action, suit or proceeding except in any such court.
                    SECTION
8.10.  
Dispute Resolution. Except to the limited extent necessary to (i) avoid expiration of a claim, (ii) comply with deadlines under applicable Law, or (iii) obtain interim relief, including injunctive relief, to
preserve the status quo or prevent irreparable harm, neither Party shall file an action or institute legal proceedings with respect to any dispute, controversy or claim arising out of this Agreement or the validity, interpretation, breach or
termination thereof, including claims seeking redress or asserting rights under any Law, until:
 18

Table of Contents

                    (a)      the aggrieved Party has given the
other Party written notice (“Notice of Disagreement”), in accordance with Section 8.01 of this Agreement, of its grievance setting forth the basis for such dispute and the remedy desired;
                    (b)      the other Party has failed to provide a prompt and effective remedy (in the
view of the aggrieved Party);
                    (c)      the aggrieved Party has
requested in writing senior executives for both Parties to promptly meet and discuss the matter detailed in the Notice of Disagreement in order to consider informal and amicable means of resolution; and
                    (d)      (i) the senior executives for both Parties have met at least three times and
have not been able to resolve the dispute to the mutual satisfaction of the Parties or (ii) more than sixty (60) Business Days have passed since the date of the Notice of Disagreement.
                    SECTION 8.11.  
Counterparts. This Agreement may be executed and delivered (including by facsimile transmission) in one or more counterparts, and by the different Parties in separate counterparts, each of which when executed shall be
deemed to be an original, but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by facsimile shall be effective as delivery of a manually executed
counterpart of this Agreement.
                    SECTION 8.12.  
No Waiver. The failure of either Party to enforce at any time for any period the provisions of or any rights deriving from this Agreement shall not be construed to be a waiver of such provisions or rights or the right of
such Party thereafter to enforce such provisions.
                    SECTION 8.13.  
Independent Contractor. In performing under this Agreement, each Party shall be acting as an independent contractor and shall not be considered or deemed to be an agent, employee, joint venturer, or partner of the other
Party. Each Party shall at all times maintain complete control over its personnel and operations. Neither Party shall have, or shall represent that it has any power, right or authority to bind the other Party to any obligation or liability, or to
assume or create any obligation or liability on behalf of the other Party.
                    SECTION
8.14.  
Registration and Filing of this Agreement. Notwithstanding Article VI, to the extent, if any, that a Party concludes in good faith that it is required to file or register this Agreement or a notification thereof with any
governmental authority, including, without limitation, the U.S. Securities and Exchange Commission, the Competition Directorate of the Commission of the European Communities, the U.S. Department of Justice or the U.S. Federal Trade Commission, in
accordance with Law, such Party shall inform the other Party thereof, and both Parties shall cooperate each at its own expense in such filing or notification and shall execute all documents reasonably required in connection therewith. In such filing
or registration, the Parties shall request confidential treatment of sensitive provisions of the Agreement, to the extent permitted by Law. The Parties shall promptly inform each other as to the activities or inquiries of any such governmental
authority relating to this Agreement and shall cooperate to respond to any request for further information therefrom on a timely basis.
 19

Table of Contents

                    IN WITNESS WHEREOF, BSC and the Company have caused this Agreement to
be executed as of the date first written above by their respective officers thereunto duly authorized.

		
	BOSTON SCIENTIFIC CORPORATION	CORAUTUS GENETICS INC.

 

				
	 By:	/s/ LAWRENCE C. BEST	 By:
 	/s/ RICHARD E. OTTO
	 	
	 	

	 	Lawrence C. Best	 	Richard E. Otto
	 	Senior Vice President & Chief	 	Chief Executive Offier
	 	Financial Officer	 	 

 20

Table of Contents

 
Exhibit A
 Clinical Plan
 ***
 ________
 “***” indicates redacted confidential information pursuant to a confidential treatment request filed with the SEC. 
  
 A-1

Table of Contents

 
Exhibit B
 Initial Forecast of BSC’s VEGF-2 Requirements
 100mg of VEGF-2 per three-month period with
initial delivery of the first three-month supply one month from the Effective Date.
 1

Table of Contents

 
Exhibit C
 Material Transfer Agreement (VEGF-2)
          THIS
MATERIAL TRANSFER AGREEMENT is made the ____ day of _______, 2003, by and between CORAUTUS GENETICS INC., a Delaware Corporation (“Corautus”), and BOSTON SCIENTIFIC CORPORATION, a Delaware corporation
(“BSC”).
  W  I  T  N  E  S  S  E  T  H:
          WHEREAS, Corautus and BSC have entered into a Development Agreement, dated July 30, 2003, pursuant to which Corautus and BSC have agreed to cooperate to develop certain
products that use VEGF-2 for the treatment of cardiovascular and vascular diseases; and
          WHEREAS, BSC desires to use, and Corautus has agreed to transfer
to BSC, quantities of a VEGF-2 plasmid DNA material for the purpose of conducting certain pre-clinical research pursuant to the Development Agreement and the terms and conditions set forth in this Agreement;
          NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained and other good and valuable consideration, the Parties agree as
follows:
 ARTICLE I
 DEFINITIONS
          1.01     
Definitions.  For purposes of this Agreement, the following capitalized terms shall have the following respective means. Capitalized terms used but not otherwise defined in this Agreement shall have the meaning ascribed to such
terms in the Development Agreement.
                       (a)
        “Biological Materials” means the Human Genome Sciences angiogenic agent licensed to and being further developed and modified by Corautus, sometimes referred to as Vascular Endothelial
Growth Factor 2 plasmid DNA, and any modifications or improvements thereto, and all related materials, all as provided by Corautus to BSC under this Agreement.
                       (b)        “ Development Agreement” means
the Development Agreement, dated July 30, 2003, between Corautus and BSC, together with all amendments thereto.
                       (c)         “Agreement” means this
Material Transfer Agreement, together with all Appendices attached hereto and all amendments hereto executed by both Parties.
 ARTICLE II
 SUPPLY OF MATERIALS AND SCOPE OF
USE
          2.01      Supply of Biological Materials.  Upon execution of this Agreement, Corautus shall supply to
BSC *** the Biological Materials (subject to Section 2.06 of the Development Agreement) for the purposes stated herein. Biological Materials supplied hereunder shall be made available for shipment at Corautus’s designated shipment point for
delivery arranged by BSC. All costs and expenses for shipping shall be borne by BSC.
 _________
 “***”
indicates redacted confidential information pursuant to a confidential treatment request filed with the SEC. 
 1

Table of Contents

          2.02      Scope of Use.  BSC may use the Biological Materials only as provided in Section
2.06 of the Development Agreement or as provided in Attachment A hereto. Without limiting the foregoing, BSC shall not use any Biological Materials in human subjects in any manner including, but not limited to, the treatment, diagnosis,
prognosis or other evaluation of patients, or for commercial purposes other than for development of Principal Products as provided in this Agreement and the Development Agreement. No Biological Materials may be exported or otherwise transferred
outside of the United States without the prior written consent of Corautus. BSC shall provide Corautus with periodic written reports as may be mutually agreed to by the Parties summarizing the results and data from the pre-clinical research project
performed pursuant hereto.
          2.03      Compliance with Laws.  BSC shall use, handle, store and dispose of the
Biological Materials in a safe manner and in compliance with all applicable federal, state and local laws and regulations, including, without limitation, all requirements and guidelines of the National Institutes of Health and the Food and Drug
Administration and all requirements relating to human and animal subjects and recombinant DNA. BSC and Corautus shall also comply with all applicable laws relating to the delivery of Biological Materials provided hereunder. Without limiting the
foregoing, all Biological Materials provided hereunder should be considered experimental in nature, may contain hazardous properties and should be handled by BSC with appropriate safety precautions.
 ARTICLE III
 LICENSES AND INTELLECTUAL PROPERTY
          3.01      No Licenses.  No
licenses are provided to BSC under any Intellectual Property rights of Corautus under this Agreement.
          3.02     
Transfers. BSC shall retain physical control of the Biological Materials and shall not sell, license, distribute or otherwise transfer or provide access to any Biological Materials, or any portion thereof, to any other Person without the
prior written consent of Corautus.
          3.03      Ownership and Integrity.  BSC acknowledges and agrees that
Corautus retains ownership of all right, title and interest in and to the Biological Materials. BSC shall not analyze, or have analyzed, the composition or formulation of any Biological Materials.
          3.04      Confidential Information.  Any Confidential Information of Corautus provided to BSC in connection with this Agreement
shall be deemed to be Confidential Information of Corautus and shall be subject to protection in accordance with the terms of Article VI of the Development Agreement.
 ARTICLE IV
 TERM
AND TERMINATION
          4.01      Term. This Agreement shall be effective as of ____________________, 2003 and shall
continue in effect unless and until terminated as provided herein.
          4.02      Termination of Agreement.
 2

Table of Contents

                       (a)        
Termination for Convenience.  Either Party may, subject to its obligations under the Development Agreement, terminate this Agreement at any time upon at least thirty (30) days’ prior written notice to the other
Party.
                       (b)         Remedies for
Default.  If any Party breaches this Agreement or the Development Agreement and does not cure such breach within twenty (20) days of receipt of written notice thereof from another Party, any non-breaching Party shall have the right to
terminate this Agreement and/or seek any and all remedies available at law or in equity.
                       (c)         Termination of Development
Agreement.  This Agreement shall immediately terminate upon the termination of the Development Agreement for any reason.
          4.03      Disposal of Biological Materials.  Upon the termination of this Agreement for any reason, BSC shall immediately
discontinue its use of the Biological Materials and destroy or return, at Corautus’s request, all quantities of Biological Materials in its possession.
 ARTICLE V

MISCELLANEOUS
          5.01      Development Agreement.  This Agreement and the performance by the Parties
hereunder shall be subject to the terms and conditions of the Development Agreement.
          5.02      Amendment.  No
amendment or modification of the terms or provisions of this Agreement shall be binding unless the same shall be in writing and duly executed by both Parties.
          5.03      Survival.  The Parties’ respective obligations hereunder which by their nature would continue beyond the
termination, cancellation or expiration of this Agreement (including, without limitation, Sections 3.03 and 4.03) shall so survive.
          5.04      Counterparts and Facsimile.  This Agreement may be executed in multiple counterparts, each of which shall be deemed to
be an original and all of which, when taken together, shall constitute one instrument. This Agreement may be executed and delivered by facsimile.
          IN
WITNESS WHEREOF, the Parties have signed this Agreement to be effective as of the date first above written.

	 		 	 	
	CORAUTUS GENETICS INC.,	 	BOSTON SCIENTIFIC CORPORATION,
	a Delaware Corporation	 	a Delaware Corporation
	 	 	 	 	 
	By: 	    	 	By: 	    
	 	 
 	 	 	 
 
	Name:	 	 	Name:	 
	 	 
 	 	 	 
 
	Its:	 	 	Its: 	 
	 	 
 	 	 	 
 

 3

Table of Contents

 
Exhibit D
 Material Transfer Agreement (Injection Catheters)
          THIS MATERIAL TRANSFER AGREEMENT is made the ____ day of _______, 2003, by and between CORAUTUS GENETICS INC., a Delaware Corporation (“Corautus”),
and BOSTON SCIENTIFIC CORPORATION, a Delaware corporation (“BSC”).
  W  I  T  N  E  S  S  E  T 
H:
          WHEREAS, Corautus and BSC have entered into a Development Agreement, dated July 30, 2003, pursuant to which Corautus and BSC have agreed to
cooperate to develop certain products that use VEGF-2 for the treatment of cardiovascular and vascular diseases; and
          WHEREAS, Corautus desires to use,
and BSC has agreed to transfer to Corautus, certain quantities of injection catheters for certain pre-clinical research purposes pursuant to the Development Agreement and the terms and conditions set forth in this Agreement;
          NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained and other good and valuable consideration, the Parties agree as
follows:
 ARTICLE I
 DEFINITIONS
          1.01     
Definitions.  For purposes of this Agreement, the following capitalized terms shall have the following respective means. Capitalized terms used but not otherwise defined in this Agreement shall have the meaning ascribed to such
terms in the Development Agreement.
                       (a)
        “ Catheter Materials” means the injection catheters known as the StilettoTM manufactured by BSC, including improvements, modifications and replacements thereto, and all related
materials, all as provided by BSC to Corautus under this Agreement.
                       (b)
        “ Development Agreement” means the Development Agreement, dated July 30, 2003, between Corautus and BSC, together with all amendments thereto.
                       (c)         “ Agreement” means this
Material Transfer Agreement, together with all Appendices attached hereto and all amendments hereto executed by both Parties.
 ARTICLE II
 SUPPLY OF MATERIALS AND SCOPE OF
USE
          2.01      Supply of Catheter Materials.  Upon execution of this Agreement, BSC shall supply to
Corautus *** the Catheter Materials (subject to Section 2.10 of the Development Agreement) for the purposes stated herein.
          2.02      Scope of Use.  Corautus may use the Catheter Materials only as provided in Section 2.08 of the Development Agreement or
as provided in Attachment A hereto. No
 _________
 “***” indicates redacted confidential
information pursuant to a confidential treatment request filed with the SEC. 
 1

Table of Contents

 Catheter Materials may be exported or otherwise transferred outside of the United States without the prior written consent of BSC.
                    2.03         Compliance with Laws.   Corautus shall
use, handle, store and dispose of the Catheter Materials in a safe manner and in compliance with all applicable federal, state and local laws and regulations, including, without limitation, all requirements and guidelines of the National Institutes
of Health and the Food and Drug Administration and all requirements relating to human and animal subjects. BSC and Corautus shall also comply with all applicable laws relating to the delivery of Catheter Materials provided hereunder. Without
limiting the foregoing, all Catheter Materials provided hereunder should be handled by Corautus with appropriate safety precautions.
 ARTICLE III
 LICENSES AND INTELLECTUAL
PROPERTY
                     3.01         No Licenses.
   No licenses are provided to Corautus under any Intellectual Property rights of BSC under this Agreement.
                     3.02         Transfers.   Corautus shall retain
physical control of the Catheter Materials and shall not sell, license, distribute or otherwise transfer or provide access to any Catheter Materials, or any portion thereof, to any other Person except for purposes of performing its obligations under
this Agreement and the Development Agreement, all in accordance with the Clinical Plan.
                     3.03         Ownership and Integrity.   Corautus
acknowledges and agrees that BSC retains ownership of all right, title and interest in and to the Catheter Materials. Corautus shall not analyze, or have analyzed, the structure or mechanics of any Catheter Materials.
                     3.04         Confidential Information.   Any
Confidential Information of BSC provided to Corautus in connection with this Agreement shall be deemed to be Confidential Information of BSC and shall be subject to protection in accordance with the terms of Article VI of the Development
Agreement.
 ARTICLE IV 
 TERM AND TERMINATION
                     4.01         Term.   This Agreement shall be effective
as of ____________________, 2003 and shall continue in effect unless and until terminated as provided herein.
                     4.02         Termination of Agreement.
                                    (a)
        Termination for Convenience.   Either Party may, subject to its obligations under the Development Agreement, terminate this Agreement at any time upon at least thirty (30) days’ prior
written notice to the other Party.
                                    (b)
        Remedies for Default.   If any Party breaches this Agreement or the Development Agreement and does not cure such breach within twenty (20) days of receipt of written notice thereof from
another Party, any non-breaching Party shall have the right to terminate this Agreement and/or seek any and all remedies available at law or in equity.
 2

Table of Contents

                                    (c)
        Termination of Development Agreement.   This Agreement shall immediately terminate upon the termination of the Development Agreement for any reason.
                     4.03         Disposal of Catheter Materials.   Upon
the termination of this Agreement for any reason, Corautus shall immediately discontinue its use of the Catheter Materials and destroy or return, at BSC’s request, all quantities of Catheter Materials in its possession.
 ARTICLE V 
 MISCELLANEOUS
                     5.01
        Development Agreement.   This Agreement and the performance by the Parties hereunder shall be subject to the terms and conditions of the Development Agreement.
                     5.02         Amendment.   No amendment or modification
of the terms or provisions of this Agreement shall be binding unless the same shall be in writing and duly executed by both Parties.
                     5.03         Survival.   The Parties’ respective
obligations hereunder which by their nature would continue beyond the termination, cancellation or expiration of this Agreement (including, without limitation, Sections 3.03 and 4.03) shall so survive.
                     5.04         Counterparts and Facsimile.   This
Agreement may be executed in multiple counterparts, each of which shall be deemed to be an original and all of which, when taken together, shall constitute one instrument. This Agreement may be executed and delivered by facsimile.

                    IN WITNESS WHEREOF, the Parties have signed this Agreement to be effective as of the date
first above written.

	 	 	 	 	 
	CORAUTUS GENETICS INC.,	 	BOSTON SCIENTIFIC CORPORATION,
	a Delaware Corporation	 	a Delaware Corporation
	 	 	 	 	 
	By:	 	 	By:	 
	 	
	 	 	

	Name:	 	 	Name:	 
	 	
	 	 	

	Its:	 	 	Its:	 
	 	
	 	 	

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]